James K. GalbraithZymeworks Reports $48.7M Q2 Revenue, FDA Clears IND for ZW251100% left coverage1 source
James K. GalbraithZymeworks Reports $48.7M Q2 Revenue, FDA Clears IND for ZW251100% left coverage1 source
James K. GalbraithZymeworks Receives Conditional NMPA Approval for HER2+ Biliary Tract Cancer in China100% left coverage1 source
James K. GalbraithZymeworks Receives Conditional NMPA Approval for HER2+ Biliary Tract Cancer in China100% left coverage1 source
James K. GalbraithTrump Administration Suspends NIH Grants, Threatens Research Nationwide100% center coverage1 source
James K. GalbraithTrump Administration Suspends NIH Grants, Threatens Research Nationwide100% center coverage1 source